Evidence map›Paper›PMID 39339748›Full record

Trial reportNutrients2024

An Oral Botanical Supplement Improves Small Intestinal Bacterial Overgrowth (SIBO) and Facial Redness: Results of an Open-Label Clinical Study.

Mildred Min, Dawnica Nadora, Mincy Chakkalakal, Nasima Afzal, Chaitra Subramanyam, Nimrit Gahoonia, Adrianne Pan, Shivani Thacker, Yvonne Nong, Cindy J Chambers and 1 more

Abstract readClinical Trial
In one paragraph

Trial report in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. The exposomal imprint on rosacea: More than skin deep.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Review
  2. BiombalanceAntioxidants (Basel, Switzerland) · 2025
    Article
  3. Article
  4. Article
  5. Activity of BiocidinFrontiers in antibiotics · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mildred MinIntegrative Skin Science and Research, Sacramento, CA 95815, USA.ORCID 0000-0002-6201-7401
Dawnica NadoraIntegrative Skin Science and Research, Sacramento, CA 95815, USA.
Mincy ChakkalakalIntegrative Skin Science and Research, Sacramento, CA 95815, USA.
Nasima AfzalIntegrative Skin Science and Research, Sacramento, CA 95815, USA.
Chaitra SubramanyamIntegrative Skin Science and Research, Sacramento, CA 95815, USA.ORCID 0000-0002-4963-4747
Nimrit GahooniaIntegrative Skin Science and Research, Sacramento, CA 95815, USA.
Adrianne PanIntegrative Skin Science and Research, Sacramento, CA 95815, USA.ORCID 0000-0001-6906-9979
Shivani ThackerIntegrative Skin Science and Research, Sacramento, CA 95815, USA.ORCID 0000-0002-6043-456X
Yvonne NongIntegrative Skin Science and Research, Sacramento, CA 95815, USA.
Cindy J ChambersIntegrative Skin Science and Research, Sacramento, CA 95815, USA.
Raja K SivamaniIntegrative Skin Science and Research, Sacramento, CA 95815, USA.ORCID 0000-0001-7205-8162

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSmall intestinal bacterial overgrowth (SIBO) is a common, yet underdiagnosed, gut condition caused by gut dysbiosis. A previous study has shown the potential of herbal therapy, providing equivalent results to rifaximin.

objectivesThe objective of this study was to assess how the use of an oral botanical regimen may modulate the gut microbiome, facial erythema, and intestinal permeability in those with SIBO.

methodsThis was an open-label prospective study of adults that had lactulose breath test-confirmed SIBO. Participants received a 10-week oral supplementation of a Biocidin liquid tincture and GI Detox+. If participants were found to be non-responsive to treatment after 10 weeks with a persistently positive lactulose breath test, a third oral supplement, Olivirex, was administered for an additional 4 weeks. Lactulose breath tests were administered at baseline, weeks 6, 10, and 14 to assess for SIBO status. A high-resolution photographic analysis system was utilized to analyze changes in facial erythema. Stool sample collections and venipuncture were performed to analyze the gut microbiome and intestinal permeability.

resultsA total of 33 subjects were screened with breath testing, and 19 subjects were found to have SIBO. Three of the subjects withdrew during the screening period prior to baseline, and sixteen subjects enrolled. Four subjects dropped out after baseline. Hydrogen-dominant SIBO was the most common subtype of SIBO, followed by methane and hydrogen sulfide. The botanical regimen was most effective for hydrogen- and hydrogen sulfide-dominant SIBO, leading to negative breath test results at week 10 in 42.8% and 66.7% of participants, respectively. Compared to baseline, supplementation with the botanical regimen led to positive shifts in short-chain fatty acid-producing bacteria such as

conclusionsSupplementation with an antimicrobial botanical supplemental regimen may have therapeutic potential in hydrogen and hydrogen-sulfide subtypes of SIBO. Furthermore, the botanical supplemental regimen may reduce facial erythema, increase SCFA-producing bacteria, decrease the F/B ratio, and modulate markers of intestinal permeability.

Indexed as

Breath TestsDietary SupplementsGastrointestinal MicrobiomeIntestine, SmallAdministration, OralAdultAgedBlind Loop SyndromeDysbiosisErythemaFaceFemaleHumansLactuloseMaleMiddle AgedLactulosebotanicalfacial erythemagut microbiomegut–skin axisrosaceaSIBO

Identifiers

PMID39339748
PMCPMC11435404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.